ArticleTranslational andrology and urology2025
Identification of molecular subtypes and prognostic risk model of glucocorticoid-related lncRNAs in bladder cancer to evaluate prognosis and immunological characteristics.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decoding the role of exosomes in bladder cancer: focusing on tumor progression and immune microenvironment modulation.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bladder cancer (BC) heterogeneity presents significant challenges in prognosis and personalized therapy. Long non-coding RNAs (lncRNAs) have been increasingly considered to be critical regulatory elements in tumor biology, and glucocorticoids exert complex effects on tumor biology. This investigation aimed to recognize glucocorticoid-related lncRNAs (GR-lncRNAs) and construct a prognostic signature for BC, elucidating their roles in subtype identification, prognosis, and immune characteristics. Methods: We retrieved messenger RNA (mRNA) expression profiles, mutation information, and clinical data for BC from The Cancer Genome Atlas (TCGA) repository. Glucocorticoid-associated genes were identified from GeneCards. Differentially expressed GR-lncRNAs were screened employing limma and Spearman correlation. We utilized univariate Cox regression, the least absolute shrinkage and selection operator (LASSO) method, and multivariate Cox regression analyses to generate the prognostic signature. We performed immune infiltration analysis [single-sample gene set enrichment analysis (ssGSEA), CIBERSORT, ESTIMATE, immunophenoscore (IPS), and Tumor Immune Dysfunction and Exclusion (TIDE)], enrichment analysis [gene set enrichment analysis (GSEA), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG)], tumor mutational burden (TMB) assessment, and drug sensitivity prediction. Furthermore, molecular subtypes relying on GR-lncRNAs were classified through non-negative matrix factorization (NMF) clustering. Results: Seven GR-lncRNAs were identified to establish a prognostic framework with strong predictive capability. Patients with high-risk status had significantly unfavorable survival prognoses, higher immune checkpoint (ICP) expression, and suppressed immune infiltration. Functional enrichment analysis revealed distinct biological processes (BPs) and pathways between risk groups. Two molecular subtypes based on these lncRNAs displayed divergent survival patterns and immune profiles, indicating potential therapeutic implications. Conclusions: Our study presents a novel GR-lncRNA-based prognostic model and molecular subtypes for BC, providing valuable insights into disease heterogeneity and offering potential biomarkers for improved prognostic assessment and personalized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.